​

Structure Therapeutics (GPCR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

GPCR Stock Forecast

Structure Therapeutics (GPCR) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $108.67, with a high of $145.00 and a low of $70.00. This represents a 100.76% increase from the last price of $54.13.

- $30 $60 $90 $120 $150 High: $145 Avg: $108.67 Low: $70 Last Closed Price: $54.13

GPCR Stock Rating

Structure Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 14 Strong Sell Sell Hold Buy Strong Buy

GPCR Price Target Upside V Benchmarks

TypeNameUpside
StockStructure Therapeutics100.76%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1212
Avg Price Target$111.00$90.50$100.75
Last Closing Price$54.13$54.13$54.13
Upside/Downside105.06%67.19%86.13%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 264101--15
Jul, 264111--16
Jun, 264111--16
May, 264121--17
Apr, 264111--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 07, 2026Canaccord Genuity$111.00$52.62110.95%105.06%
Jun 11, 2026Ananda GhoshH.C. Wainwright$70.00$41.5368.55%29.32%
Apr 27, 2026Canaccord Genuity$101.00$45.49122.03%86.59%
Mar 17, 2026Evan SeigermanBMO Capital$145.00$56.88154.92%167.87%
Jan 20, 2026Guggenheim$140.00$88.6457.94%158.64%
Jan 19, 2026Goldman Sachs$102.00$88.6415.07%88.44%
Dec 19, 2025Ananda GhoshH.C. Wainwright$90.00$66.4535.44%66.27%
Dec 12, 2025Terence FlynnMorgan Stanley$125.00$66.2488.71%130.93%
Dec 11, 2025Jefferies$125.00$69.6479.49%130.93%
Dec 08, 2025Stifel Nicolaus$90.00$69.9828.61%66.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 07, 2026CitigroupMarket OutperformMarket Outperformhold
Jun 11, 2026H.C. WainwrightBuyBuyhold
Mar 17, 2026BMO CapitalOutperformOutperformhold
Mar 16, 2026William BlairOutperformOutperformhold
Mar 16, 2026Leerink PartnersOutperformOutperformhold
Jan 20, 2026GuggenheimBuyBuyhold
Jan 06, 2026BMO CapitalOutperformOutperformhold
Dec 19, 2025H.C. WainwrightBuyBuyhold
Dec 12, 2025Morgan StanleyOverweightOverweighthold
Dec 12, 2025CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.43$-2.34$-2.40---
Avg Forecast$-0.83$-0.80$-0.81$-1.52$-1.97$-2.05
High Forecast$-0.78$-0.73$2.53$-1.05$-1.08$-2.05
Low Forecast$-0.87$-1.00$-2.05$-2.18$-3.15$-2.05
Surprise %192.77%192.50%196.30%---

Revenue Forecast

$145M $156M $167M $178M $189M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$45.45M-$148.80M$199.50M
High Forecast--$45.45M-$148.80M$199.50M
Low Forecast--$45.45M-$148.80M$199.50M
Surprise %------

Net Income Forecast

$-2B $-900M $-300M $300M $900M $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-89.62M$-122.53M$-141.20M---
Avg Forecast$-363.78M$-380.80M$-119.43M$-712.07M$-933.34M$-902.74M
High Forecast$-345.07M$-322.71M$1.11B$-461.62M$-477.92M$-902.74M
Low Forecast$-382.49M$-438.89M$-901.73M$-962.52M$-1.39B$-902.74M
Surprise %-75.36%-67.82%18.23%---

GPCR Forecast FAQ

Is Structure Therapeutics stock a buy?

Structure Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Structure Therapeutics is a favorable investment for most analysts.

What is Structure Therapeutics's price target?

Structure Therapeutics's price target, set by 14 Wall Street analysts, averages $108.67 over the next 12 months. The price target range spans from $70 at the low end to $145 at the high end, suggesting a potential 100.76% change from the previous closing price of $54.13.

How does Structure Therapeutics stock forecast compare to its benchmarks?

Structure Therapeutics's stock forecast shows a 100.76% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Structure Therapeutics over the past three months?

  • August 2026: 26.67% Strong Buy, 66.67% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.

What is Structure Therapeutics’s EPS forecast?

Structure Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.52, marking a -36.67% decrease from the reported $-2.4 in 2025. Estimates for the following years are $-1.97 in 2027, and $-2.05 in 2028.

What is Structure Therapeutics’s revenue forecast?

Structure Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $148.8M, and $199.5M for 2028.

What is Structure Therapeutics’s net income forecast?

Structure Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-712M, representing an 404.29% increase from the reported $-141M in 2025. Projections indicate $-933M in 2027, and $-903M in 2028.